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Objective: To prepare a website for families and health
professionals containing up to date information about
paediatric rheumatic diseases (PRD).
Methods: Firstly, paediatric rheumatology centres and family
self help associations were surveyed to characterise current
clinical practice of physicians providing care for children with
PRD, research activities, and training facilities of each centre.
Secondly, international consensus was reached on the
content of the website. Finally, the website was developed
and the texts translated.
Results: The web page contains three main sections: (a)
description for families of the characteristics of 15 PRD; (b)
list of paediatric rheumatology centres; (c) contact informa-
tion for family self help associations. A version for 45
countries in 52 languages (with another three in progress) is
now available on the web. 291 surveys from 171 centres and
102 family associations were received from 42 countries. The
median proportion of time spent in paediatric practice in the
centres examined was 100%, with 70% of this time dedicated
to paediatric rheumatology. 90% of the centres were willing
to perform clinical trials in the future.
Conclusions: The PRINTO/PRES website provides a well
defined and competent set of information about PRD, with
appropriate multiple translated versions and easy web
navigational direction.
P
aediatric rheumatic diseases (PRD) are rare conditions
with substantial morbidity, with significant conse-
quences for the quality of life of the child and his/her
family, as well as the costs of health care and social care. The
PRD comprise a group of heterogeneous chronic diseases,
including juvenile idiopathic arthritis, juvenile systemic lupus
erythematosus, juvenile dermatomyositis, juvenile sclero-
derma, and vasculitides.
Widespread availability of the internet allows families to
access medical information quickly and easily, but this
information is often not standardised, and is inaccurate
and unreliable. Indeed, internet philosophy is that anyone
can set up a website, but with the risk that, through
ignorance or bias, the content of the site may not be correct
even if the original information sources are reliable and
accurate.
The European Commission,1 and the American Medical
Association,2 have formulated guidelines for the development
of websites containing medical information. The Paediatric
Rheumatology International Trials Organization (PRINTO)3
in collaboration with the Paediatric Rheumatology European
Society (PRES), supported by the European Union (contract
2001CVG4–808), has set up a project with the aim of
preparing a website for families and health professionals.
This website would contain consensus information about
many of the PRD, a list of paediatric rheumatology centres,
and a list of family self help associations. Moreover, in order
to characterise the current clinical practice of physicians who
provide care for children with PRD, research activities, and
training facilities of each centre a survey was sent to
paediatric rheumatology centres in 44 countries.
All information is available in the national language(s) of
all the countries belonging to the PRINTO/PRES networks
(www.pediatric-rheumatology.printo.it).
METHODS
PRINTO and PRES networks
PRINTO3 is a non-profit international public network
established in 1996 by 14 European countries (now including
44 countries and more than 180 centres world wide), which
aims at fostering, facilitating, and coordinating the develop-
ment, conduct, analysis, and reporting of studies to evaluate
the efficacy and safety of drug treatments, quality of life, and
outcome for children with PRD. PRINTO is composed of
academic or clinical centres, or both, actively engaged in the
research and clinical care of children with PRD.
PRES is an international scientific society for European
healthcare professionals (and non-Europeans as associate
members) working in the field of paediatric rheumatology.
The mission of PRES is to promote knowledge of PRD,
stimulate research in the field, disseminate knowledge
through scientific meetings and publications, provide guide-
lines and standards for good clinical practice, for the training
of doctors and allied health professionals in the practice of
paediatric rheumatology.
Abbreviations: PRD, paediatric rheumatic diseases; PRES, Paediatric
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Phases of the project
Phase 1
The first phase comprised a survey of existing paediatric
rheumatology centres and family self help associations in the
countries that were members of PRINTO/PRES. Information
was gathered through a questionnaire devised by PRINTO,
and approved by PRES, sent to paediatric rheumatology
centres in 44 countries, in order to characterise the current
clinical practice of physicians who provide care for children
with PRD, research activities, and training facilities of each
centre. For the purpose of the survey a paediatric rheumatol-
ogist was defined as a physician whose workload consists of
more than 50% paediatric rheumatology, or who is board
certified in paediatric rheumatology, or who is recognised as
one of the hospital/region/state acknowledged experts in
paediatric rheumatology. Only the centres completing the
survey were offered the opportunity to be listed on the
website.
The survey was divided into sections in order to collect
reliable information about:
N Section a: Demographics. Complete address of the centre with
title, hospital, phone, fax, email, and website.
N Section b: Characteristics of the patient population of each centre.
Time devoted to paediatric practice, total number of
patients followed up, and new cases in the past year for
all PRD; number of inpatients, outpatients, and paediatric
rheumatology consultations for other departments in a
typical week.
N Section c: Professional, teaching, and research activities. Time
spent in patient care, teaching, clinical and/or laboratory
research, administrative duties, etc; time spent in patients’
care; presence of general paediatrics and/or paediatric
rheumatology fellows and/or visiting fellows from other
hospitals/countries; official recognition of paediatric rheu-
matology as a paediatric subspecialty.
N Section d: Clinical trials background. Number and type of
paediatric and/or paediatric rheumatology clinical trials
performed in the past 4 years and/or in progress; will-
ingness to participate in future paediatric rheumatology
clinical trials or reasons for inability to participate.
N Section e: Information on the centre. Type of hospital (children
or general, or both; tertiary centre, affiliation to medical
school); catchment area of the hospital with number of
people; list of permanent staff dealing with paediatric
rheumatology in the centre.
N Section f: Family help associations. Complete address of family
self help association, phone, fax, email, and website.
N Section g: Curriculum vitae information. Age, English knowl-
edge; year of graduation from medical school; specialties
completed; years of experience in paediatric rheumatology,
etc.
N Section h: Workforce information. Current workforce provision
in each centre and information about planned future
development of paediatric rheumatology in each country.
Phase 2
An international consensus conference was held on 1–2
March 2003 in Genoa (Italy), where 30 physicians dealing
with PRD (the PRINTO national coordinators representing
each of the countries in the network) gathered to reach
consensus about the content of the web page, identification
of rules and working groups for the preparation of documents
to be released on the web, and identification of a referent
physician for each centre participating in the project to whom
the general public can address their request for information.
Each working group was assigned the task of preparing the
master document on a specific PRD in the English language.
The master documents for the PRD were then reviewed by all
PRINTO national coordinators and, finally, the revised
English version was translated into the languages of each
country participating in the project.
Phase 3
The final phase, which was run in parallel with the previous
two, was devoted to the development of the website. Two
research coordinators with expertise in website development
were specifically assigned to the preparation of the website
and related database, while three other research assistants
maintained contact with all the centres belonging to PRINTO/
PRES.
The website was developed with active server page
technology (language visual basic script) directly connected
to a Microsoft Access database located on the web server. The
maps for all countries were developed as a ‘‘map system’’
using dynamic Macromedia Flash maps. In the ‘‘informa-
tion’’ section (see below), all the documents are available
both in html and Adobe PDF format.
General methodology
The project was conducted using well recognised consensus
formation methodology specifically designed to combine
judgments from a group of experts in a particular field: the
Delphi Technique and Nominal Group Technique.4 5 The
Delphi Technique uses a series of well defined questionnaire
based surveys. The Nominal Group Technique is a structured
face to face meeting designed to facilitate reaching consensus
on the topic field of study. These techniques have been used
extensively in the past.6 7 Consensus formation methodology
must be designed so that each step is based on the results of
the previous steps.
RESULTS
Content of the website
Forty five countries (52 languages) have been completed and
are already on line (fig 1). The translation was original (from
the consensus English version to the language of the country)
for the following 29 countries (31 languages): Bulgaria,
China, Croatia, Czech Republic, Denmark, Egypt, Finland,
France, Georgia, Germany, Greece, Hungary, India, Israel,
Italy, Japan, Latvia, Lithuania, Netherlands, Norway, Poland,
Portugal, Russia, Serbia Montenegro, Slovakia, Slovenia,
South Korea, Spain (Castilian, Catalan, and Galician),
Turkey, United Kingdom.
The translation was adapted from the original languages
for the following 15 countries (20 languages): Argentina,
Australia, Austria, Belgium (Flemish and French), Brasil,
Chile, Costa Rica, Cuba, Ireland, Luxembourg (French,
German), Mexico, Singapore (English and Chinese), Saudi
Arabia, Switzerland (French, German and Italian), Tunisia.
For a further three countries translation is in progress:
Albania, Iran, Sweden.
The flags of all countries participating in the project with
the names of each state translated into appropriate languages
are listed on the home page of the website (http://
www.pediatric-rheumatology.printo.it). Because this page
has to be accessed by people with different languages the
initial connection was visually prepared making it as simple
as possible to facilitate navigation.
The click on a flag links to the section specific to that
country. For each country there is a translated introductory
statement and three specific sections. The general structure is
the same for all countries.
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First section
The first section aims at giving families an up to date
description of the characteristics of the listed PRD. Each text
is written in the frequently asked questions format (What is
it? How frequent is it? etc).
Specific text can be found for the following diseases:
juvenile idiopathic arthritis, juvenile systemic lupus erythe-
matosus (including antiphospholipid antibodies, and neona-
tal lupus), juvenile dermatomyositis, juvenile scleroderma,
juvenile spondyloarthropathies, Kawasaki’s disease, Henoch-
Scho¨nlein purpura, primary systemic vasculitis (polyarteritis
nodosa, Takayasu’s arteritis, Wegener’s granulomatosis,
other vasculitides), rheumatic fever and post-streptococcal
reactive arthritis, Behc¸et’s disease, Lyme arthritis, pain
syndromes (fibromyalgia syndrome, growing pains, benign
hypermobility syndrome, etc), recurrent fevers related to a
genetic anomaly (tumour necrosis factor receptor associated
periodic syndrome, mevalonate kinase associated periodic
fever syndrome, or hyper-IgD syndrome, etc), familial
Mediterranean fever, drug treatment (non-steroidal anti-
inflammatory drugs, ciclosporin, intravenous immuno-
globulins, corticosteroids, azathioprine, cyclophosphamide,
methotrexate, hydroxychloroquine, sulfasalazine, colchicine,
anti-tumour necrosis factor agents).
Second section
The second section lists the paediatric rheumatology centres
existing in that country. Information about a specific centre
can be accessed via the list of centres or visually via the map
of the country where all the centres are depicted. For each
Figure 1 Home page of the website
and home page specific for Italy with
terms in Italian. The structure of the
home page for each country is the same
as for Italy with all the terms translated
into the language of the specific
country.
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centre the name of the responsible physician and the
permanent staff with colour photos, complete address,
telephone, fax, email, and hospital website are provided.
Families can reach physicians by email with a direct link and
can also get specific information on the hospital through the
direct link to its website. The steering committee of the
project decided to put on the web only the contact
information (address) to avoid any judgment about the
quality of the centre. This list will be updated regularly and
does not pretend to be exhaustive.
Third section
The third section gives the contact information for the family
help associations (charities or similar) that can be found in
the different countries, with a link to their email and website.
Web questionnaire survey
Section a: Demographics
The survey was sent to 229 centres, members of PRINTO and/
or PRES. A total of 291 surveys were received from 42
different countries, with some centres sending more than one
survey. To avoid redundancy in the results, for the purposes
of the analysis we considered only the survey completed by
the centre director for a total of 171/229 (75%).
All the values reported in the following sections are
medians if not otherwise specified.
Section b: Characteristics of the patient population
of each centre
Because some paediatric patients are seen in a hospital for
adults we wanted to check the proportion of paediatric
practice in the centres examined and found that it was equal
to 100%, with only 10 centres (6%) dealing with less than
50% of paediatric patients. Juvenile idiopathic arthritis was
the most frequent PRD seen, followed by juvenile systemic
lupus erythematosus.
In a typical week (taking the median value) within a
centre, 2 inpatient, 28 outpatient, and 4 paediatric rheuma-
tology consultations were conducted for other departments.
Section c: Professional, teaching, and research
activit ies
Table 1 reports the median time spent for professional,
teaching, and research activities. Most of the time (58%) is
dedicated to patient care, with 70% of this time dedicated to
paediatric rheumatology patients. The time dedicated to
laboratory research is limited and with a wide range of
variation from centre to centre, while distribution of efforts
was similar for other responsibilities, such as teaching,
clinical research, and administrative duties.
Section d: Clinical trials background
A total of 131/158 (83%) centres had participated in at least
one paediatric clinical trial in the past 4 years (median three
paediatric trials, of which two where paediatric rheumatology
trials).
A total of 154/171 (90%) centres were willing to perform
future investigator initiated clinical trials, while a smaller
number of centres 138/171 (81%) were willing to participate
in pharmaceutical company sponsored clinical trials, which
usually require more time.
For the centres that did not want to participate in future
paediatric rheumatology clinical trials the two main reasons
listed were that they do not have time to participate and/or
that they do not sufficient manpower and support.
Section e: Information on the centre
A hospital website was available in 121 (71%) centres; this
information might be an underestimate because it is based
mainly on information provided by the centres.
A total of 68/154 (44%) centres were paediatric hospitals
only, 53 (34%) were general hospitals, and 33 (21%) both.
There are 146/154 (95%) tertiary care centres and 141 of the
154 (92%) centres are affiliated to a medical school, with 123/
154 (80%) centres located in an area with at least 500 000
inhabitants.
Section f: Family help association
The survey identified 103/164 (63%) family help associations
(charities or similar); of these, 51 (50%) provided a website.
Section g: Curriculum vitae information
For this section the analysis was performed for all surveys
received.
Fifty five per cent (89/162) of units that responded to the
survey were directed by female physicians. Their median age
was 48 years (32–64). Of the 261 physicians who responded
to the survey, 150/242 (62%) were women, with a median age
of 48 years.
Physicians had a median of 24 years (range 7–55) of
medical experience, with a median of 13 years (0.3–37) of
specific experience in paediatric rheumatology.
For non-English speaking countries, knowledge of English
was characterised as basic in 47 (21%), good in 94 (41%), and
fluent in 88 (38%) respondents.
Section i: Workforce information
The great majority of the paediatric rheumatologists in the
survey 82/132 (62%) did not consider that other specialists
were competing to take over the care of children with PRD
over the past 2 years.
There is a need to increase the number of paediatric
rheumatologists in the area/region around each hospital for
86/145 (59%) respondents, and the need is even greater in
each country for 105/146 (72%) but, despite this necessity,
84/146 (58%) think that no other paediatric rheumatologist
will be employed, in the next 5 years. The paediatric
rheumatology practice in each area is expanding for 124/
148 (84%), but the job opportunities in the near future will
stay the same for 80/144 (56%).
Despite the perceived manpower shortages the morale for
the great majority (107/142 (75%)) of paediatric rheumatol-
ogy centres is good/excellent.
DISCUSSION
Families can now access the internet for health information
with greater ease, but the quality of the available information
is not always good. To provide good quality information for
the families of children with PRD, PRINTO and PRES
undertook this project to develop a consensus derived website
Table 1 Proportion of time spent by professional,
teaching, and research activities
Time spent (median; min-max)
(n = 164)
Patient care:
Paediatric rheumatology 70 (2–100)
General paediatric 30 (0–93)
Adult rheumatology 10 (0–90)
Teaching 10 (0–70)
Clinical research 10 (0–85)
Laboratory research 0 (0–40)
Administrative duties 10 (0–65)
Results are shown as percentages.
The sum of the median frequencies does not add up to 100%.
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responding to published guidelines,1 2 8 which can be
regarded as a model for future development of a website
containing standardised and up to date medical information
directed to families and health professionals.
The website has just been completed and, so far, its
promotion among potential users is only at the initial stage. It
is expected that once specific links to our website are
developed in well established national sites, the number of
connections will increase. Despite this initial limitation, a
consistent number of hits have already taken place. In March
2004 about 3000 people a month visited the site, with more
than 13 000 specific pages accessed from 64 countries. This
number increased to 9000 visitors a month from 85 countries
in June. At the end of February when we started to advertise
the website among all the physicians and family help
associations in the PRINTO/PRES mailing list (about 800
contacts), access increased from the first to the second week
of March by 166%.
Many users came from small countries who wrote ‘‘key-
words’’ in their own national language instead of English.
Our website greatly facilitates the access for families to
medical information translated into their own language.
Access to physicians and hospitals is sometimes difficult
owing to time constraints and heavy work schedules, and the
possibility of reaching the hospital by email will surely
facilitate family-doctor relations.
It is a recognised limitation of the texts on PRD provided by
this website, that in this first phase they were prepared just
by physicians, with limited input from family associations or
allied health professionals. Future revisions of the available
brochures will have to take into account comments coming
directly from families.
Over the past 30 years, paediatric rheumatology has
evolved from a small group of internists and paediatricians
interested in childhood rheumatic diseases to a board
certified subspecialty, at least in some countries, and is
established as a subsection of paediatrics within the Union of
European Medical Specialists (UEMS), which reports to the
EU commission.
Most of the centres surveyed were located in tertiary
hospitals in highly populated areas. As observed in general
paediatrics most of the practising physicians are female
(62%), while 55% of physicians in charge of their units are
women also.
The clinical practice load was high with little time left for
research. Despite this limitation, 80% of the centres examined
had participated in at least one clinical trial during the past 4
years. This high level of participation may be due to two main
factors. Firstly, we surveyed members of PRINTO, a big
international network with the specific aim of carrying out
collaborative clinical research, and so there is a built-in bias.
PRINTO has connections all over the world, including areas,
like Latin America, which were previously not included in
international studies. Secondly, the paediatric rule issued by
the Food and Drug Administration (FDA)9 10 that now
requires manufacturers of products likely to be used in
children to study those products in the relevant paediatric
population. Similar rules are currently discussed also by the
European Medical Evaluation Agency (EMEA).11 12
From the survey, it is quite clear that future development
in the field should deal with national regulations facilitating
the establishment of paediatric rheumatology centres in a
less well served area and establishing the minimum and
maximum numbers of specialists needed.
In conclusion, visitors to the PRINTO/PRES website are
given a well defined and competent set of information about
PRD, with appropriate multiple translated versions and easy
web navigational directions. A by-product is important
practice information from the survey of clinical centres and
clinical practice in the participating countries.
ACKNOWLEDGEMENTS
We are indebted to Drs Monica Tufillo, Elisabetta Maggi, and Anna
Tortorelli for their help in data handling, organisational skills, and
overall management of the project.
Supported by the Directorate of Public Health of the European Union
(contract No 2001CVG4–808) and by IRCCS G Gaslini of the
University of Genoa, Genoa, Italy.
Authors’ affiliations
. . . . . . . . . . . . . . . . . . . . .
N Ruperto, P Garcia-Munitis, L Villa, M Pesce, A Martini, IRCCS G.
Gaslini, Pediatria II Reumatologia, PRINTO, Genova, Italy
A Aggarwal, Sanjay Gandhi Institute of Medical Sciences, Lucknow,
India
A Fasth, The Queen Silvia Children’s Hospital, Go¨teborg, Sweden
T Avcin, University Medical Centre Ljubljana, Ljubljana, Slovenia
S-C Bae, The Hospital for Rheumatic Diseases, Hanyang University
Medical Centre, Seoul, South Korea
Z Balogh, National Institute of Rheumatology and Physiotherapy,
Budapest, Hungary
C Li, Beijing Children’s Hospital, Capital, Beijing, China
J De Inocencio, CS Estrecho de Corea, Madrid, Spain
M Dibra, University Hospital Centre Mother Terza, Tirana, Albania
P Dolezalova, 1st Faculty of Medicine and General Faculty Hospital,
Prague, Czech Republic
Y E Miedany, Ain Shams University, Cairo, Egypt
B Flato, Rikshospitalet University Hospital, Oslo, Norway
M Harjacek, Children’s Hospital Zagreb, Zagreb, Croatia
H-I Huppertz, Zentralkrankenhaus, Bremen, Germany
F Kanakoudi-Tsakalidou, Aristotle University of Thessaloniki -
Ippokration General Hospital, Thessaloniki, Greece
N Wulffraat, Wilhelmina Kinderziekenhuis, Utrecht, Netherlands
P Lahdenne, Hospital for Children and Adolescents, Helsinki University
Central Hospital, Helsinki, Finland
J A Melo-Gomes, Instituto Portugues de Reumatologia, Lisbon, Portugal
D Mihaylova, University Children Hospital, Sofia, Bulgaria
S Nielsen, Juliane Marie Centret, Rigshospitalet, København, Denmark
I Nikishina, Institute of Rheumatology RAMS, Moscow, Russia
H Ozdogan, Cerrahpasa Tip Faku¨ltesi, Istanbul, Turkey
K Pagava, Tbilisi State Medical University, Tbilisi, Georgia
V Panaviene, Vilnius University, Vilnius, Lithuania
A-M Prieur, Hoˆpital Necker Enfants Malades, Paris, France
A-M Romicka, Institute of Rheumatology, Warsaw, Poland
I Rumba, University of Latvia, Riga, Latvia
N Shafaie, Iran University of Medical Sciences, Teheran, Iran
G Susic, Institute of Rheumatology, Belgrade, Belgrade, Serbia
Montenegro
S Takei, Faculty of Medicine, Kagoshima University, Kagoshima city,
Japan
Y Uziel, Meir Medical Centre, Kfar Saba, Israel
R Vesely, University Hospital, Kosice, Slovakia
P Woo, Great Ormond Street Children Hospital, London, UK
A Martini, Universita` di Genova, Genova, Italy
Additional PRINTO national coordinators who adapted the original
translation to the language of their country: Sulaiman Al-Mayouf, MD
(Riyadh, Saudi Arabia), Boel Andersson-Gare (Jonkoping, Sweden),
Rym Hajri Ben Ammar, MD (El Menzah, Tunisia), Ruben Burgos-Vargas,
MD (Mexico City, Mexico), Cecilia Coto Hermosilla, MD (Habana,
Cuba), Carmen de Cunto, MD (Buenos Aires, Argentina), Stella Maris
Garay, MD (La Plata, Argentina), Michae¨l Hofer, MD (Lausanne,
Switzerland), Christian Huemer, MD, Prof (Bregenz, Austria), Rik Joos,
MD (Gent, Belgium), Anton Jordi, MD (Barcelona, Spain), Claudia
Machado, MD (Botucatu, Brasil), Marta Miranda, MD (Providencia
Santiago de Chile, Chile), Kevin Murray, MB.BS., FRACP (Perth, WA,
Australia), Oscar Porras, MD, PhD Chief Immunology (San Jose, Costa
Rica), Madeleine Rooney, MD, MRCP (Belfast, Ireland), Yvonne See, MD
(Singapore, Singapore), Charles Spencer (Chicago, IL, USA).
All authors declare that they (a) provided a substantial contribution to the
conception and design, or acquisition of data, or analysis and
interpretation of data; (b) participated in the drafting the article or
revising it critically for important intellectual content; (c) approved the
final version to be published; (d) have no relevant financial interest in the
manuscript.
Website for the paediatric rheumatic diseases 1105
www.annrheumdis.com
group.bmj.com on June 13, 2015 - Published by http://ard.bmj.com/Downloaded from 
Written permission was obtained from all people named in the
‘‘Acknowledgements’’.
Correspondence to: Dr N Ruperto, Paediatric Rheumatology
INternational Trials Organisation (PRINTO), IRCCS G. Gaslini, Pediatria
II Reumatologia, Largo Gaslini, 5, 16147 Genova, Italy; nicolaruperto@
ospedale-gaslini.ge.it
Accepted 15 December 2004
Published Online First 10 March 2003
REFERENCES
1 Commission of the European Communities, Brussels, Belgium. eEurope
2002: quality criteria for health related websites. J Med Internet Res
2002;4:e15.
2 Winker MA, Flanagin A, Chi-Lum B, White J, Andrews K, Kennett RL, et al.
Guidelines for medical and health information sites on the internet - principles
governing AMA web sites. JAMA 2000;283:1600–6.
3 Ruperto N, Martini A. International research networks in pediatric
rheumatology: the PRINTO perspective. Curr Opin Rheumatol
2004;16:566–70.
4 Delbecq AL, Van de Ven AH, Gustafson DH. Group Techniques for program
planning. A guide to nominal group and Delphi processes, 1st ed. Glenview,
Ill. : Scott, Foresman and Company, 1975.
5 Sniderman AD. Clinical trials, consensus conferences, and clinical practice.
Lancet 1999;354:327–30.
6 Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary
definition of improvement in juvenile arthritis. Arthritis Rheum
1997;40:1202–9.
7 Ruperto N, Ravelli A, Murray KJ, Lovell DJ, Andersson-Gare B, Feldman BM,
et al. Preliminary core sets of measures for disease activity and damage
assessment in juvenile systemic lupus erythematosus and juvenile
dermatomyositis. Rheumatology (Oxford) 2003;42:1452–9.
8 Prady SL, Norris D, Lester JE, Hoch DB. Expanding the guideline for electronic
communication with patients. Application to a specific tool. J Am Med Inform
Assoc 2001;8:344–8.
9 Connor JD. A look at the future of pediatric therapeutics: an investigator’s
perspective of the new pediatric rule. Pediatrics 1999;104:610–13.
10 FDA. Regulations requiring manufacturers to assess the safety and
effectiveness of new drugs and biologic products in pediatrics patients (21 CFR
Parts 201, 312, 314, and 601). Federal Register 1998:63.
11 Ruperto N, Martini A, for the Paediatric Rheumatology International Trials
Organization (PRINTO). Use of unlabelled and off licence drugs in children. A
European paediatric rule is needed to protect children. BMJ
2000;320:1210–11.
12 European Commission. Proposal for a regulation of the European Parliament
and of the Council on medicinal products for paediatric use and amending
Regulation (EEC). No 1768/92, Directive 2001/83/EC and Regulation (EC)
No 726/2004. Available at http://pharmacos.eudra.org/F2/Paediatrics/
docs/_2004_09/EN.pdf (accessed 8 April 2005).
1106 Ruperto, Garcia-Munitis, Villa, et al
www.annrheumdis.com
group.bmj.com on June 13, 2015 - Published by http://ard.bmj.com/Downloaded from 
www.pediatric-rheumatology.printo.it
of children with rheumatic diseases: 
PRINTO/PRES international website for families
Shafaie, G Susic, S Takei, Y Uziel, R Vesely, P Woo and A Martini
H Ozdogan, K Pagava, V Panaviene, A-M Prieur, A-M Romicka, I Rumba, N 
Nikishina,Wulffraat, P Lahdenne, J A Melo-Gomes, D Mihaylova, S Nielsen, I 
Miedany, B Flato, M Harjacek, H-I Huppertz, F Kanakoudi-Tsakalidou, N
S-C Bae, Z Balogh, C Li, J De Inocencio, M Dibra, P Dolezalova, Y El 
N Ruperto, P Garcia-Munitis, L Villa, M Pesce, A Aggarwal, A Fasth, T Avcin,
doi: 10.1136/ard.2004.030221
2005
2005 64: 1101-1106 originally published online March 10,Ann Rheum Dis 
 http://ard.bmj.com/content/64/7/1101




This article cites 7 articles, 2 of which you can access for free at: 
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on June 13, 2015 - Published by http://ard.bmj.com/Downloaded from 
